Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by B Group Inc.

Core Viewpoint - B Group Inc. has reduced its stake in Ultragenyx Pharmaceutical by 24.0%, indicating a shift in investment strategy while other investors are increasing their positions in the company [2][3]. Investment Activity - B Group Inc. now holds 135,000 shares of Ultragenyx Pharmaceutical after selling 42,600 shares, representing approximately 3.1% of its investment portfolio [2]. - Assetmark Inc. increased its stake by 1,706.7%, now owning 1,084 shares valued at $33,000 after purchasing an additional 1,024 shares [3]. - Huntington National Bank boosted its position by 56.2%, owning 1,092 shares worth $33,000 after acquiring 393 additional shares [3]. - Smartleaf Asset Management LLC increased its stake by 205.4%, now holding 1,738 shares valued at $53,000 after acquiring 1,169 shares [3]. - Covestor Ltd raised its position by 26.0%, owning 1,787 shares valued at $54,000 after purchasing 369 additional shares [3]. - Institutional investors and hedge funds collectively own 97.67% of Ultragenyx Pharmaceutical's stock [3]. Stock Performance - Ultragenyx Pharmaceutical's stock opened at $21.34, with a 52-week low of $18.41 and a high of $42.37 [4]. - The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -3.65, and a beta of 0.16 [4]. - The stock's fifty-day moving average is $23.01, and the 200-day moving average is $28.83 [4]. Earnings Results - The company reported an EPS of ($1.29), missing analysts' consensus estimates of ($1.20) by ($0.09) [4]. - Revenue for the quarter was $207.28 million, exceeding expectations of $199.60 million, representing a year-over-year increase of 25.5% [4]. - Ultragenyx had a negative return on equity of 1,024.42% and a negative net margin of 85.54% [4]. - Analysts forecast an EPS of -5.18 for the current fiscal year [4]. Insider Trading - EVP Karah Herdman Parschauer sold 8,135 shares at an average price of $22.80, totaling $185,478, representing a 9.63% decrease in ownership [5]. - CEO Emil D. Kakkis sold 54,404 shares at an average price of $22.80, totaling $1,240,411.20, representing a 7.63% decrease in ownership [5]. - Insiders sold a total of 104,958 shares valued at $2,394,858 over the last three months, with insiders currently owning 5.50% of the stock [5]. Recent Developments - Ultragenyx reported positive results from a Phase-3 trial for its AAV8 gene therapy (DTX301), which reduced ammonia levels by approximately 18% compared to placebo [6]. - The trial results are significant as they advance the program toward potential regulatory and commercial milestones [6]. Analyst Ratings - Guggenheim reduced its target price from $64.00 to $52.00 while maintaining a "buy" rating [7]. - Bank of America lowered its target from $72.00 to $58.00, also maintaining a "buy" rating [7]. - HC Wainwright decreased its price target from $60.00 to $50.00, keeping a "buy" rating [7]. - Robert W. Baird reduced its target from $72.00 to $47.00, maintaining an "outperform" rating [7]. - Sixteen analysts rated the stock as a "Buy," one as "Hold," and one as "Sell," with an average rating of "Moderate Buy" and a consensus price target of $65.76 [7].